

STATE-OF-THE-ART PAPER

Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding

Udaya S. Tantry, PhD,* Laurent Bonello, MD, PhD,† Daniel Aradi, MD, PhD,‡
Matthew J. Price, MD,§ Young-Hoon Jeong, MD, PhD,|| Dominick J. Angiolillo, MD, PhD,¶
Gregg W. Stone, MD,# Nick Curzen, BM (HONS), PhD,** Tobias Geisler, MD,††
Jurrien ten Berg, MD, PhD,‡‡ Ajay Kirtane, MD, SM,# Jolanta Siller-Matula, MD, PhD,§§
Elisabeth Mahla, MD,|||| Richard C. Becker, MD,¶¶ Deepak L. Bhatt, MD, MPH,##
Ron Waksman, MD,*** Sunil V. Rao, MD,††† Dimitrios Alexopoulos, MD,‡‡‡
Rossella Marcucci, MD, PhD,§§§ Jean-Luc Reny, MD, PhD,||||| Dietmar Trenk, PhD,¶¶¶
Dirk Sibbing, MD,### Paul A. Gurbel, MD,* for the Working Group on
On-Treatment Platelet Reactivity

Baltimore, Maryland; Marseille, France; Balatonfüred, Hungary; La Jolla, California; Jinju, South Korea; Jacksonville, Florida; New York, New York; Southampton, United Kingdom; Tübingen, Bad Krozingen, and Munich, Germany; Vienna and Graz, Austria; Durham, North Carolina; Boston, Massachusetts; Washington, DC; Patras, Greece; Florence, Italy; and Geneva, Switzerland

Dual antiplatelet therapy with aspirin and a P2Y₁₂ receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention ischemic events for various platelet function tests (PFTs). Updated American and European practice guidelines have issued a Class IIb recommendation for PFT to facilitate the choice of P2Y₁₂ receptor inhibitor in selected high-risk patients treated with percutaneous coronary intervention, although routine testing is not recommended (Class III). Accumulated data from large studies underscore the importance of high on-treatment platelet reactivity to ADP as a prognostic risk factor. Recent prospective randomized trials of PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of current PFT platforms can actually influence outcomes. However, there are major limitations associated with these randomized trials. In addition, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Therefore, a therapeutic window concept has been proposed for P2Y₁₂ inhibitor therapy. In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events. In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy. (J Am Coll Cardiol 2013;62:2261–73) © 2013 by the American College of Cardiology Foundation

From the *Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland; †Département de Cardiologie, Hôpital Universitaire Nord, Aix-Marseille University, Marseille, France; ‡Department of Cardiology, Heart Center Balatonfüred, Balatonfüred, Hungary; §Scripps Clinic and Scripps Translational Science Institute, La Jolla, California; ||Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University, Jinju, South Korea; ¶Cardiovascular Research Center, University of Florida College of Medicine, Jacksonville, Florida; #Cardiovascular Research and Education, Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; **Wessex Cardiothoracic Unit, University Hospital, Southampton National Health Service Foundation Trust, Southampton, United Kingdom; ††Medizinische Klinik III,

Kardiologie und Kreislauferkrankungen, Universitätsklinikum Tübingen, Tübingen, Germany; ††Department of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands; §§Department of Cardiology, Medical University of Vienna, Vienna, Austria; ||||Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria; ¶¶Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; ##Veterans Affairs Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; ***Interventional Cardiology, Medstar Washington Hospital Center, Washington, DC; †††The Duke Clinical Research Institute, Durham, North Carolina; †††Department of Cardiology, Patras University Hospital, Patras, Greece; §§§Department of Medical and Surgical Critical Care, University of Florence,

Abbreviations and Acronyms

ACS	= acute coronary syndrome(s)
ADP	= adenosine diphosphate
CABG	= coronary artery bypass graft
CAD	= coronary artery disease
CI	= confidence interval
HPR	= high platelet reactivity to adenosine diphosphate
HR	= hazard ratio
LPR	= low platelet reactivity to adenosine diphosphate
MI	= myocardial infarction
OR	= odds ratio
PCI	= percutaneous coronary intervention
PFT	= platelet function testing/test
PR	= platelet reactivity
PRI	= platelet reactivity index
PRU	= P2Y ₁₂ reaction units
ROC	= receiver-operating characteristic
ST	= stent thrombosis
TIMI	= Thrombolysis In Myocardial Infarction
VASP-P	= vasodilator-stimulated phosphoprotein-phosphorylation

Dual antiplatelet therapy with aspirin and a P2Y₁₂ receptor blocker to inhibit platelet reactivity (PR) and to prevent ischemic event occurrences is an effective pharmacologic therapy administered to patients with acute coronary syndromes (ACS) or those undergoing percutaneous coronary intervention (PCI) (1–3). Except for recommendations related to some specific demographic variables, for example, the history of transient ischemic attack or stroke that precludes prasugrel use in ACS undergoing PCI, a “one-size-fits-all” approach for P2Y₁₂ receptor blockers is mostly employed based on clinical trial results. However, the pharmacodynamic effect of clopidogrel has been shown to be widely variable, whereas prasugrel and ticagrelor are associated with a more uniform antiplatelet response (4–10).

In the past decade, compelling evidence from numerous observational studies has emerged demonstrating a strong association between high platelet reactivity to adenosine diphosphate (HPR) and post-PCI ischemic events, especially stent thrombosis (ST) (4). Earlier, we provided a consensus opinion on the definition of HPR based on various methods

reported in the literature (4). Since then, updated American College of Cardiology Foundation/American Heart Association/Society for Cardiovascular Angiography and Interventions and European Society of Cardiology guidelines issued a Class IIb recommendation for platelet function testing (PFT) to facilitate the choice of P2Y₁₂ inhibitor in selected, high-risk patients undergoing PCI, although routine PFT is not recommended (Class III, no benefit) (Online Appendix, Box-1) (1–3). Recent prospective randomized trials evaluating personalized antiplatelet therapy based on PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of PFT can actually influence outcomes (11–13). It should be acknowledged that these randomized trials are associated with major limitations. There are also controversies regarding the low positive predictive value of PFT, which some investigators have proposed has limitations in its clinical utility for individual patients. However, others have argued that an application of diagnostic test statistics is not appropriate for a prognostic test such as PFT (14–16). In this updated consensus document, we aim to review the available evidence addressing the relation of PR to thrombotic and bleeding events. We propose updated cutoff values for HPR and low platelet reactivity to adenosine diphosphate (LPR) that might be used in future investigations of personalized antiplatelet therapy. Finally, we highlight the major limitations of the randomized trials that failed to demonstrate the utility of PFT.

Many of the earlier studies that attempted to link ex vivo evidence of heightened PR to ischemic events were criticized for the potential introduction of artifacts by the laboratory methods. The findings were regarded as “unconvincing” because the PFT were thought to be poor substitutes for the complex interactions taking place in vivo (17). Correlations between various assays were not robust; moreover, there was poor agreement between tests in discriminating patients

Florence, Italy; |||||Department of Internal Medicine, Rehabilitation, and Geriatrics, Geneva Platelet Group, Geneva University Hospitals and School of Medicine, Geneva, Switzerland; ¶¶¶Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany; and the ###Department of Cardiology, Ludwig-Maximilians Universität München, Medizinische Klinik und Poliklinik I, Munich, Germany. Dr. Tantry has received payment for lectures and travel support from Accumetrics. Dr. Bonello has received lecture and consulting fees from sanofi-aventis, AstraZeneca, and Eli Lilly; and grants from Assistance Publique Hôpitaux de Marseille and AstraZeneca. Dr. Aradi has received consulting fees from Verum Diagnostica; and lecture fees from Verum Diagnostica, Roche, DSI/Lilly, AstraZeneca, Pfizer, Bayer AG, Abbott, and Krka. Dr. Price has received speaking fees from AstraZeneca and Daiichi Sankyo/Lilly & Co.; consulting fees from AstraZeneca, Daiichi Sankyo/Lilly & Co., Janssen Pharmaceuticals, Accumetrics, The Medicines Company, Merck & Co., Inc., Mediceur, Boston Scientific, Bristol-Myers Squibb/sanofi-aventis, Terumo, and St. Jude Medical; and equity interest in Iverson Genetics. Dr. Jeong has received honoraria for lectures from sanofi-aventis, Daiichi Sankyo/Lilly, Nanosphere, Haemonetics, and Otsuka; and research grants or support from Dong-A Pharmaceuticals, Han-mi Pharmaceuticals, Boehringer-Ingelheim, Otsuka, Accumetrics, and Haemonetics. Dr. Angiolillo has received consulting fees or honoraria from Bristol-Myers Squibb, sanofi-aventis, Eli Lilly, Daiichi Sankyo, The Medicines Company, AstraZeneca, Merck & Co., Inc., Evolva, Abbott Vascular, and PLx Pharma; payment for participation in review activities from Johnson & Johnson, St. Jude Medical, and Sunovion; institutional payments for grants from Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Otsuka, Eli Lilly, Daiichi Sankyo, The Medicines Company,

AstraZeneca, and Evolva; and he has received an Esther and King Biomedical Research Grant. Dr. Stone has received consulting fees from Boston Scientific, Eli Lilly, Daiichi Sankyo, and AstraZeneca. Dr. Curzen has received unrestricted grants from Haemonetics, St. Jude Medical, and Medtronic; and speaker/consulting fees from Haemonetics, St. Jude Medical, Boston Scientific, Medtronic, Abbott Vascular, and Daiichi Sankyo/Lilly. Dr. Geisler has received consulting fees from Daiichi Sankyo, Lilly, Bayer, and AstraZeneca; lecture fees from Bayer, Daiichi Sankyo, and The Medicines Company; and restricted grants from Daiichi Sankyo, The Medicines Company, and Siemens Healthcare. Dr. ten Berg has received lecture and consulting fees from AstraZeneca, Merck & Co., Inc., Eli Lilly, and Daiichi Sankyo. Dr. Siller-Matula has received lecture or consulting fees from AstraZeneca, Daiichi Sankyo, and Eli Lilly; and has received a research grant from Roche Diagnostics. Dr. Mahla has received study grants from CSL Behring Biotherapies for Life and NovoNordisk Pharma; and has received lecture fees from CSL Behring Biotherapies for Life and Boehringer Ingelheim. Dr. Becker has received research support from AstraZeneca and the National Heart, Lung and Blood Institutes; educational grants from Pfizer and AstraZeneca; and honoraria for his service on the scientific advisory boards for Daiichi-Sankyo and Portola. Dr. Bhatt serves on the advisory boards of Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; he is the on board of directors of Boston VA Research Institute and Society of Cardiovascular Patient Care; he is the chair of the American Heart Association Get With The Guidelines Science Subcommittee; he has received honoraria from American College of Cardiology (editor, Clinical Trials, Cardiosource), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (chief medical editor,

with and without ischemic events (18,19). A large number of recent observational studies involving more than 20,000 patients demonstrated that HPR during clopidogrel treatment is a strong and independent risk factor for post-PCI thrombotic events (20–23). In addition, the most widely used assays (VerifyNow P2Y₁₂ assay [Accumetrics, San Diego, California], Multiplate Analyzer [F. Hoffmann-La Roche Ltd., Basel, Switzerland], vasodilator-stimulated phosphoprotein-phosphorylation [VASP-P] assay [Diagnostica Stago, Biocytex, Asnières, France]) have overcome many of the technical and methodological limitations of previous assays, including conventional light transmittance aggregometry.

Platelet Function Measurement in Patients Undergoing PCI

Recently, the multinational prospective registry study ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) (~50% of patients with ACS) reinforced the independent association between HPR and definite/probable ST (16). In this study, HPR (>208 P2Y₁₂ reaction units [PRU]) was independently associated with an ~3-fold increased risk for 30-day definite/probable ST (propensity-adjusted hazard ratio [HR]: 3.00, 95% confidence interval [CI]: 1.39 to 6.49; *p* = 0.005). Furthermore, >208 PRU remained an independent predictor of 1-year definite/probable ST (adjusted HR: 2.49, 95% CI: 1.43 to 4.31; *p* = 0.001) and myocardial infarction (MI) (adjusted HR: 1.42, 95% CI: 1.09 to 1.86; *p* = 0.01). Although significantly more patients with HPR had died at 1-year follow-up, HPR was not an independent predictor of mortality after adjusting for a large number of confounding variables (HR: 1.20, 95% CI: 0.85 to 1.70; *p* = 0.30). The authors observed that HPR had a greater impact in ACS patients than in stable coronary artery disease (CAD) patients (16).

The importance of HPR and treatment with intensified therapy should be interpreted in the context of patient characteristics such as ethnicity and underlying risk. In a study of 1,220 East Asian patients, HPR (>272 PRU) was associated with cardiovascular events at 1-year follow-up

among acute MI patients, whereas there was no relation in those without acute MI (24). Similarly, Park *et al.* (25) demonstrated that HPR >235 PRU was independently associated with the primary composite endpoint of death, MI, ST, or stroke in East Asian patients undergoing PCI with ACS, but not with stable CAD patients.

There is further support for an association between HPR determined *ex vivo* and coronary atherosclerosis and thrombotic event occurrence *in vivo*. HPR (>230 PRU) during clopidogrel therapy was independently associated with greater coronary artery atherosclerotic burden and plaque calcification as measured by intravascular ultrasound imaging (26). An association between PR and systemic inflammation/procoagulant marker elevation has also been described in patients with CAD (27–29). In addition to the extensive literature on HPR in clopidogrel-treated patients, recent observational studies suggest that HPR is also relevant to the new P2Y₁₂ receptor blockers (6,9,10).

In summary, the evidence that supports the potential utility of PFT as a prognostic marker among patients undergoing PCI includes: 1) the accepted highly platelet-related pathophysiology of atherothrombosis and its clinical phenotypes; 2) the consistent confirmation of an association between HPR and ischemic event occurrence; 3) the results of randomized clinical trials demonstrating lower thrombotic event rates in patients treated with pharmacodynamically more potent agents than clopidogrel; and 4) lack of difference in the final mechanism of action between P2Y₁₂ receptor blockers. From a statistical perspective, PFT fulfills several criteria as a robust prognostic marker. In particular, HPR is associated with substantial hazard for thrombotic events (11) and improves net reclassification for major adverse clinical events (16,21).

Platelet Function Measurement in Medically-Managed Patients

Although prognostic utility of HPR is robust in patients undergoing PCI, its clinical relevance in medically-managed ACS patients or in stable CAD patients is less clear. In a recent study, antiplatelet drug responsiveness assessed by several assays did not add any incremental predictive value

Cardiology Today Intervention), WebMD (continuing medical education steering committees); he is a senior associate editor for Journal of Invasive Cardiology; he sits on the data monitoring committees of the COMPLETE (Complete Versus Culprit Revascularization in STEMI), and TOTAL (A Randomized Trial of Routine Aspiration Thrombectomy With PCI Versus PCI Alone in Patients With STEMI Undergoing Primary PCI) studies; he has received research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, sanofi-aventis, The Medicines Company; and he has performed unfunded research for FlowCo, PLx Pharma, and Takeda. Dr. Rao has received research funding from Ikaria and sanofi-aventis; and consulting fees/honoraria from AstraZeneca, Daiichi Sankyo Lilly, The Medicines Company, Terumo Medical, and ZOLL. Dr. Alexopoulos has received lecture fees from AstraZeneca. Dr. Marcucci has received consulting fees from Merck & Co., Inc., and Haemonetics; and lecture fees from AstraZeneca, Eli Lilly, Sharp, Dohme, and Instrumentation Laboratory. Dr. Reny has received lectures fees from Merck Sharp & Dohme. Dr. Trenk has received consulting fees from Boehringer Ingelheim, Daiichi Sankyo, and Eli Lilly; lecture fees from

AstraZeneca, Bayer Vital, Daiichi Sankyo, Eli Lilly, and Merck Sharp & Dohme; and an institutional grant from Eli Lilly. Dr. Sibbing has received consulting fees from Daiichi Sankyo, Eli Lilly, and Verum Diagnostica; and lecture fees from Roche and CSL Behring. Dr. Gurbel has received consulting fees from Daiichi Sankyo, Lilly, Pozen, Novartis, Bayer, AstraZeneca, Accumetrics, Nanosphere, sanofi-aventis, Boehringer Ingelheim, Merck & Co., Inc., Medtronic, Iverson Genetics, CSL, and Haemonetics; grants from the National Institutes of Health, Daiichi Sankyo, Lilly, Pozen, CSL, AstraZeneca, sanofi-aventis, Haemoscope, Medtronic, Harvard Clinical Research Institute, and Duke Clinical Research Institute; lecture fees, including service on Speakers' Bureaus, from Lilly, Daiichi Sankyo, Nanosphere, sanofi-aventis, Merck, and Iverson Genetics; and payment for development of educational presentations from Schering-Plough, the Discovery Channel, and Pri-Med. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received May 25, 2013; revised manuscript received July 29, 2013, accepted July 31, 2013.

over common risk factors for the occurrence of major adverse cardiovascular events at 3-year follow-up in stable patients ($n = 771$) with symptomatic atherothrombotic disease managed medically with aspirin and/or clopidogrel (30).

In the TRILOGY-ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) platelet function substudy ($n = 2,564$), the greater platelet inhibition provided by prasugrel versus clopidogrel did not translate into an improved event-free survival in the overall study (7). In an unadjusted analysis, HPR (PRU >208) was associated with the occurrence of the primary composite endpoint (cardiovascular death, MI, or stroke) through 30 months. However, in an adjusted analysis including a large number of demographic and clinical characteristics, HPR did not remain an independent predictor of adverse events (7). Some limitations merit discussion regarding the TRILOGY study. Patients were not-randomized and platelet function was not measured during the initial period of potentially highest thrombotic risk (patients were enrolled and randomized 4 to 10 days after the index event). The TRILOGY study enrolled a significant proportion of patients who did not have proven evidence of significant CAD in whom PR to adenosine diphosphate (ADP) may not have influenced outcome. Finally, the adjusted analysis included multiple risk factors and covariates that may influence thrombotic outcomes by their effect on platelet physiology and thereby could have masked the independent association of HPR on ischemic events. Although multivariable adjustment is important to suggest causal relationships between risk factors and events, univariate associations may be more important for the treating physician who is unable to adjust test results for multiple variables at the bedside. Indeed, HPR has been associated with several prognostic variables including ACS, diabetes, high body weight, older age, reduced left ventricular ejection fraction, or elevated C-reactive protein (31,32), whereas smoking has been associated with a lower frequency of HPR in some studies (33,34).

Treatment intervention based on platelet function measurement was used to reduce post-PCI thrombotic events in the GRAVITAS (Gauging Responsiveness With a VerifyNow Assay—Impact on Thrombosis and Safety) trial. PCI patients with HPR (≥ 235 PRU) were randomly assigned to either standard dose clopidogrel or a repeated 600-mg loading dose of clopidogrel followed by 150 mg daily (high dose). High-dose clopidogrel treatment was ineffective in reducing the 6-month composite ischemic event occurrence of cardiovascular death, nonfatal MI, and ST. Notably, the event rate was low (2.3% vs. 5% used for power calculation); therefore, the study was substantially underpowered (11). In addition to being underpowered, there are other potential explanations for the neutral results of GRAVITAS trial (35). In a time-dependent analysis of GRAVITAS, <208 PRU was independently associated with the 60-day primary endpoint (HR: 0.23, 95% CI: 0.05 to 0.98; $p = 0.047$) and tended to be an independent predictor at 6 months (HR:

0.54, 95% CI: 0.28 to 1.04; $p = 0.06$) (36). Only a minority of patients receiving high-dose clopidogrel achieved <208 PRU, indicating that the high-dose clopidogrel regimen may have been suboptimal. A more potent intervention that reduces HPR to a greater extent would have had greater potential to improve clinical outcomes given the very low event rate. In support of this hypothesis, the ELEVATE-TIMI 56 (Escalating Clopidogrel by Involving a Genetic Strategy—Thrombolysis In Myocardial Infarction 56) trial showed that up to 225 mg of clopidogrel might be necessary to overcome HPR in patients carrying 1 loss-of-function cytochrome *2C19* gene (37). The GRAVITAS trial enrolled a population at low absolute risk for ischemic events despite displaying HPR. The majority of patients had stable angina and were successfully treated with PCI, and periprocedural events were not included in the primary endpoint. The tested pharmacologic intervention was administered more than 12 h after PCI, and the associated acute vessel injury/stent deployment, which may have been too late to blunt a platelet-related incipient lesion. Finally, it is possible that a single PFT will not reliably reflect the effect of clopidogrel on ADP-induced PR in all patients (35).

In the ARCTIC (Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting) study, 2,440 patients were randomly assigned to either a strategy of platelet function monitoring and drug adjustment or to a conventional strategy without platelet function monitoring according to the clinicians' preference (13). The 1-year primary composite endpoint of death, MI, ST, stroke, or urgent revascularization was similar in both arms (34.6% vs. 31.1%; HR: 1.13, 95% CI: 0.98 to 1.29; $p = 0.10$), mostly driven by periprocedural MI that was assessed by nonstandard methodology (single troponin assessment 6 h after the procedure). However, protocol implementation was incomplete: 73% of patients with HPR received an additional clopidogrel loading dose, whereas only 4% received a prasugrel loading dose. Similar to the GRAVITAS trial, the primary intervention in the maintenance phase among patients with HPR was clopidogrel 150 mg, 15.6% of the patients in the monitoring group had HPR at 2- to 4-week follow-up despite monitoring, and the study population was at low absolute risk for cardiovascular events. Importantly, twice as many patients were lost to follow-up in the conventional than in the monitoring arm (3.8% vs. 1.9%). Finally, the composite endpoint in this study also included other events, such as death from any cause, that may not be related to platelet function (13).

The TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study is the only trial using a potentially effective strategy to overcome HPR. Stable angina patients with >208 PRU were randomized after successful drug-eluting stent PCI

to prasugrel or standard-dose clopidogrel. However, the study was terminated prematurely after a non-pre-specified interim analysis due to a largely lower rate of ischemic events than anticipated that precluded the establishment of meaningful results. Approximately 30% of the enrolled patients declined randomization after being identified as having HPR, which is suggestive of selection bias. The very low event rates in patients with stable CAD successfully treated with current drug-eluting stent, even among those hyporesponsive to clopidogrel, suggest that this patient population will be challenging for future studies to demonstrate the benefits of PFT-directed therapies (12).

Although the results of the latter 3 randomized trials were negative, smaller studies have suggested that the PFT-directed approach may be effective depending on the method of implementation. Two small multicenter trials employed the VASP-P assay to tailor incremental loading doses of clopidogrel to reduce on-treatment PR below the HPR cutoff. This strategy was associated with significantly reduced subsequent adverse event occurrence, including early ST without increasing bleeding (38,39). Similarly, 2 other studies have suggested that the selective administration of a glycoprotein IIb/IIIa receptor inhibitor to patients undergoing elective PCI who were identified as poor responders to aspirin or clopidogrel was effective in reducing both 30-day and 1-year ischemic events without increased bleeding rates (40,41). In addition, the non-randomized MADONNA (Multiple Electrode Aggregometry in Patients Receiving Dual Antiplatelet Therapy to Guide Treatment With Novel Platelet Antagonists) study ($n = 798$) (42) and a randomized study by Hazarbasanov *et al.* (43) suggested that an individualized antiplatelet regimen based on PFT measured by a Multiplate analyzer can reduce post-PCI ischemic event occurrences without an increase in bleeding risk. Of importance, all of these studies aimed to decrease PR below the threshold of HPR, which is associated with post-PCI ischemic events.

Finally, a meta-analysis of 9 randomized trials compared intensified antiplatelet therapy with standard therapy in patients with HPR (20). Although the analysis included some small-sized trials, and the strategy to intensify platelet inhibition was heterogeneous, the results showed a significant reduction in cardiovascular mortality and ST in HPR patients when intensified antiplatelet therapy was used. Of interest, the benefit was mostly observed in high-risk patients, suggesting that other factors, including demographic, clinical, and angiographic factors, must be also taken into consideration to optimally identify the patients at greatest risk. Along this line, recent studies have suggested that adding clinical variables and genotype to PFT may improve risk prediction (31,32).

PR and Bleeding

During the era of dual antiplatelet therapy with aspirin and ticlopidine/clopidogrel, the evaluation of antiplatelet

therapies has been largely focused on reducing ischemic event occurrence (efficacy). Bleeding (safety) was often considered as an inevitable and acceptable complication. However, in the era of more potent P2Y₁₂ receptor inhibitors, there is a heightened risk for bleeding. The balance between the absolute risk reduction in ischemic events and the absolute risk increase in bleeding events (particularly assessed by more sensitive bleeding scales) with more potent agents remains delicate. A therapeutic counterpoise may occur, with the absolute risk reduction in ischemic event occurrence and the absolute risk increase in bleedings approaching to the same magnitude (44). Current knowledge suggests that there may be a “ceiling effect” in reducing ischemic event occurrence even with new P2Y₁₂ receptor inhibitors (*i.e.*, 10% residual ischemic event occurrence). Furthermore, in the contemporary registries and trials of PCI, the absolute rate of ischemic events at 1-year follow-up is low (16,32). Given this scenario, the focus is now shifting toward finding strategies that could avoid excessive bleeding while maintaining the benefit of reduced ischemic/thrombotic events (45). This paradigm evolution also led to the introduction of novel clinical endpoints such as the “net adverse clinical events” in ongoing and future trials. It could be argued that more potent antiplatelet therapies may be optimal when the benefit of reducing ischemic events outweighs the risk of bleeding. Accordingly, the greater net clinical benefit of the more potent P2Y₁₂ blockade may be observed early after stenting when thrombotic risk is the highest (46).

Bleeding events have been associated with an increased risk of short- and long-term morbidity and mortality in CAD patients during long-term antiplatelet therapy and anticoagulant therapy (47). In addition, the results of randomized trials of anticoagulants suggest that a survival benefit might be attributable to reduction in bleeding alone (48,49). Several potential reasons for the higher risk of mortality associated with bleeding include: 1) premature termination of obligatory therapies including antiplatelet agents; 2) immunosuppression and platelet activation by blood transfusion; and 3) hemodynamic compromise associated with bleeding and greater prevalence of comorbidities in patients who suffer from bleeding events (50). In addition, inflammatory, procoagulant, and other mechanisms have been suggested as mediating factors for risk associated with bleeding and transfusion (51). Finally, even superficial or “nuisance” bleeding may be clinically important as these events are associated with premature drug discontinuation, which may have an impact on clinical outcomes (52).

Challenges in Studying Bleeding Complications

A consensus has been reached regarding the definition of ischemic events such as MI and ST (53,54). Although these ischemic events are highly platelet-dependent, the underlying mechanisms of bleeding are more complex and heterogeneous in origin. For example, the etiologies of

gastrointestinal, intracranial, surgical, and nuisance bleedings are distinct. The role that platelet function plays in these different types of bleeding might vary, and it might be related to the extent of impaired hemostatic potential and possibly a higher degree of platelet inhibition. Moreover, variable transfusion triggers and perioperatively relevant covariates have to be considered in surgery-related bleeding (55). Compared with the composite endpoint of cardiovascular death, MI, or stroke, the prevalence of “major” or “severe” bleeding is generally low; therefore, it is more difficult to study mechanisms of major bleeding as compared to ischemic event outcomes due to the large number of patients required. Moreover, characteristics such as older age, chronic kidney disease, female sex, and diabetes share heightened risk for both bleeding and ischemic events (56). Previous randomized clinical trials used various bleeding definitions, and this has produced a library of heterogeneous classifications for incidence and severity. These diverse definitions have limited comparisons of bleeding across trials (57). The Bleeding Academic Research Consortium proposed a standardized definition to better quantify bleeding events and to evaluate new strategies to reduce the risk of bleeding in future trials (48).

Relation of Platelet Function to Bleeding in PCI-Treated Patients

Although the link between HPR and ischemic event occurrence is well established, the association between on-treatment PR and bleeding events is less clear. Observational studies involving patients undergoing PCI have suggested a possible link between LPR and bleeding (Table 1) (8,9,11,13,18,58–63). A first report suggested an association between clopidogrel hyper-responsiveness (or LPR) and post-discharge TIMI minor or major bleeding events in a cohort of patients undergoing PCI for non-ST-segment elevation MI (n = 597). In this study, patients in the first quartile of 10 $\mu\text{mol/l}$ ADP-induced platelet aggregation (<40% aggregation) had more bleeding events than patients in the other quartiles did (58). Following this preliminary finding, further confirmation came from a large prospective cohort (n = 2,533) in which a relationship between post-PCI major non-coronary artery bypass graft (CABG)-related bleeding and PR was observed (8).

The link between post-PCI non-CABG-related major bleedings and LPR was also suggested by a retrospective analysis of 346 patients using the VASP-platelet reactivity index (PRI). In this study, lower PR measured by VASP-PRI was observed in patients with non-CABG-related TIMI major bleeding events, compared with patients without major bleeding ($32.5 \pm 22.4\%$ vs. $51.2 \pm 21.9\%$; $p = 0.006$) (60). These findings regarding major bleedings were reproduced in a prospective cohort of 310 patients treated with clopidogrel, demonstrating a 4.5-fold increased risk for TIMI major bleeding in patients in the lowest quartile of VerifyNow PRU levels measured before PCI.

Receiver-operating characteristic (ROC) curve analysis identified the LPR cut point of PRU ≤ 189 to be the best predictor of bleeding (61).

A link between PR and bleeding was further observed in prasugrel-treated patients. Parodi et al. (63) reported that patients undergoing PCI with LPR on prasugrel therapy had more frequent access site bleeding. Accordingly, a strong independent relationship between platelet inhibition assessed by VASP-PRI and bleeding (including non-CABG-related TIMI major or minor bleeding) during 1-year follow-up was reported in ACS patients treated with prasugrel after successful PCI. Specifically, VASP-PRI $\leq 16\%$ was associated with a higher rate of bleeding events. In multivariate analysis, VASP-PRI predicted both thrombotic and bleeding events (odds ratio [OR]: 1.44, 95% CI: 1.22 to 1.72; $p < 0.001$; and OR: 0.75, 95% CI: 0.59 to 0.96; $p = 0.024$, respectively [per 10% increase]). The frequency of thrombotic (excluding repeat revascularization) and bleeding events at 1-year follow-up were similar in this study (9). The observation of a link between non-CABG-related major bleeding and LPR during prasugrel therapy further supports the potential role of PFT, particularly as these findings do not appear to be specific for any P2Y₁₂ inhibitor. The consistent potent platelet inhibition achieved in ticagrelor-treated patients with PR values presenting within a small range have limited the ability to determine a bleeding threshold in such patients, at least by using the VerifyNow assay (64,65).

However, meaningful relationships between PR and bleeding events were not observed in large-scale platelet function studies such as the POPULAR (Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-Pretreated Patients Undergoing Elective PCI), GRAVITAS, and ARCTIC studies (11,13,18). A potential reason for the discrepancy between the results of the latter trials and those of smaller studies may be related to overall lower major bleeding event rates, different bleeding definitions, and the inclusion of procedural-related bleeding into the primary endpoints. However, in the largest study of all, ADAPT-DES (n = 8,583), HPR (>208 PRU) was inversely related to major bleeding (HR: 0.73, 95% CI: 0.61 to 0.89; $p = 0.002$) in a propensity-adjusted analysis accounting for 84 baseline and treatment-related variables (16).

Relation of PR to Surgery-Related Bleeding

Some observational studies demonstrated a relation of platelet function and bleeding in patients undergoing cardiac surgery (Table 2) (66–69). The major rationale for 5-day clopidogrel discontinuation recommended by the guidelines is the avoidance of excessive perioperative bleeding by allowing recovery of platelet function (70). However, demonstration of response variability, an $\sim 30\%$ non-responsiveness rate to clopidogrel therapy, and also variability in platelet function recovery following clopidogrel therapy cessation indicate that an objective measurement of

Table 1 Relation Between Platelet-Function Measurement and Bleeding in Patients Treated With PCI

First Author/Study (Ref. #)	Patients (n); P2Y ₁₂ Treatment	Platelet Function Test(s)	Bleeding Criteria	Outcome
Sibbing et al. (8)	PCI (n = 2,533); clopidogrel	Multiplate analyzer, ADP-induced aggregation	Procedure-related TIMI major bleeding	<188 AU associated with 3.5× bleeding
Bonello et al. (9)	ACS patients undergoing PCI (n = 301); prasugrel	VASP assay	Major and minor TIMI bleeding	VASP-PRI ≤16% associated with major bleedings
GRAVITAS (11)	PCI with DES implantation; clopidogrel	VerifyNow P2Y ₁₂ assay	GUSTO bleeding	No association between bleeding and platelet reactivity
ARCTIC (13)	PCI (n = 2,440); clopidogrel, prasugrel	VerifyNow P2Y ₁₂ assay	Major bleeding—STEEPLE trial	No association between bleeding and platelet reactivity
POPULAR (18)	PCI (n = 1,069); clopidogrel	LTA, VerifyNowP2Y ₁₂ assay; Plateletworks; IMPACT-R; PFA-100 with collagen-ADP; Innovance PFA P2Y	TIMI bleeding	No relation between bleeding and platelet reactivity measured by any assay
Cuisset et al. (58)	NSTE-ACS (n = 597); clopidogrel	LTA pre-heparin ADP-induced aggregation and VASP-PRI	Non-CABG TIMI major and minor	<40% aggregation associated with higher risk of 30 days post-discharge bleeding
Gurbel et al. (59)	PCI (n = 225); clopidogrel	MA-ADP TEG platelet mapping assay		≤31 MA-ADP associated with post-PCI bleeding
Mokhtar et al. (60)	PCI (n = 346); clopidogrel	VASP assay	Non-CABG TIMI minor and major	Low on-treatment PRI independent predictor of bleedings
Patti et al. (61)	PCI (n = 310); clopidogrel	VerifyNow P2Y ₁₂ assay	TIMI major bleeding	ROC analysis; ≤189 PRU associated with bleeding
Tsukahara et al. (62)	PCI (n = 184); clopidogrel	LTA	REPLACE 2 bleeding	First quartile of ADP-induced aggregation associated with bleeding
Parodi et al. (63)	PCI (n = 298); prasugrel	LTA	Entry site bleeding	LPR associated with bleeding

ACS = acute coronary syndromes; ADP = adenosine diphosphate; ARCTIC = Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting study; AU = arbitrary aggregation unit(s); CABG = coronary artery bypass graft; DES = drug-eluting stent(s); GRAVITAS = Gauging Responsiveness With a VerifyNow Assay—Impact on Thrombosis and Safety; GUSTO = Global Use of Strategies to Open Occluded Arteries; IMPACT-R = cone and platelet analyzer (IMPACT-R, Beersels, Belgium); LPR = low platelet reactivity to adenosine diphosphate; LTA = light transmittance aggregometry; MA = maximum amplitude; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; PFA = platelet function analyzer; POPULAR = Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-Pretreated Patients Undergoing Elective PCI study; PRI = platelet reactivity index; PRU = P2Y₁₂ reaction units; REPLACE 2 = Randomized Evaluations of PCI Linking Angiomax to Reduced Clinical Events trial; ROC = receiver-operating characteristic; STEEPLE = Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention Patients, an International Randomized Evaluation trial; TEG = thrombelastography; TIMI = Thrombolysis In Myocardial Infarction; VASP = vasodilator stimulated phosphoprotein-phosphorylation.

the antiplatelet effect of clopidogrel before surgery may obviate the need for the recommended standardized waiting period in a substantial percentage of patients (71–73).

Chen et al. (66) demonstrated that <40% pre-heparin ADP-induced aggregation predicted 92% of severe bleeding needing multiple transfusions in patients on clopidogrel undergoing first-time on-pump CABG. Recently,

the prospective TARGET-CABG (Time Based Strategy to Reduce Clopidogrel Associated Bleeding During CABG) study demonstrated that stratifying clopidogrel-treated patients on background aspirin therapy to specific waiting periods based on a pre-operative assessment of clopidogrel response resulted in similar perioperative bleeding, as determined by chest tube output and transfusion of red

Table 2 Relation Between Platelet Function Measurement and Bleeding in Patients Undergoing Cardiac Surgery

First Author (Ref. #)	Treatment	Platelet Function Test (Criteria for Bleeding)	Outcome
Chen et al. (66)	Clopidogrel (n = 45); on-pump CABG	LTA (<40% pre-heparin ADP-induced PA)	Low PA correlated with 92% of severe coagulopathies that required multiple transfusions
Mahla et al. (67)	Clopidogrel or clopidogrel-naïve on background aspirin (n = 180); on-pump CABG	MA-ADP TEG platelet mapping assay	Individualized pre-operative waiting in clopidogrel-treated patients, as compared to clopidogrel-naïve patients, resulted in similar bleeding and ~50% reduction of pre-operative waiting as compared to that recommended in the guidelines
Kwak et al. (68)	Clopidogrel and aspirin (n = 100); off-pump CABG	MA-ADP TEG platelet mapping assay (70% inhibition of PA)	Platelet inhibition >76% was the only independent predictor of post-operative transfusion requirements (OR: 11.44, 95% CI: 2.77–47.30; p = 0.001)
Ranucci et al. (69)	Clopidogrel or ticlopidine (n = 87); CABG and/or valves	Multiplate analyzer	ADP-induced platelet aggregation independently predicted bleeding (cutoff: 31 U; AUC: 0.71; p = 0.013)

AUC = area under the curve; CI = confidence interval; OR = odds ratio; PA = platelet aggregation; other abbreviations as in Table 1.

blood cells, as compared to clopidogrel-naïve patients undergoing elective first-time on-pump CABG after adjustment for potential confounders (67). In TARGET-CABG, pre-operative clopidogrel response was measured by thrombelastography with Platelet Mapping assay (Haemonetics Corporation, Braintree, Massachusetts). Surgery was scheduled with no delay in those patients with an ADP-induced platelet-fibrin clot strength (MA_{ADP}) >50 mm, within 3 to 5 days in those with an MA_{ADP} = 35 to 50 mm, and after 5 days in those with an MA_{ADP} <35 mm (59). Compared with the guidelines, this individualized approach reduced the pre-operative waiting period by about 50% (68). Considering the preliminary evidence from observational studies, the Society of Thoracic Surgeons has given a Class IIa recommendation regarding the use of PFT to assist in the timing of surgery (Online Appendix, Box-2) (70).

Therapeutic Window for P2Y₁₂ Receptor Blockade

Early small turbidimetric aggregometry-based studies demonstrated that ischemic event occurrences, including periprocedural MI and ST, were not linearly related to on-treatment PR but instead occurred above a moderate level of on-treatment PR (74). Based on this preliminary

evidence, it was first hypothesized that a “therapeutic window of PR” exists, similar to the international normalized ratio range used for warfarin therapy (74).

In the first observational study of 2,533 patients undergoing PCI, patients with >46 AU (arbitrary aggregation units) were defined as “clopidogrel low responders” based on ROC curve analysis. This cut point was associated with the primary efficacy endpoint of 30-day incidence of definite or probable ST. In contrast, patients with <19 AU were defined as “enhanced responders,” and this cut point was associated with the primary safety endpoint of in-hospital TIMI major bleeding (8). Subsequently, a MA_{ADP} >47 mm was shown to have a high predictive value for 3-year post-PCI ischemic events during dual antiplatelet therapy. Moreover, ROC curve and quartile analysis suggested $MA_{ADP} \leq 31$ mm as a predictive value for post-PCI bleeding events (59). Similarly, a therapeutic window of 86 to 238 PRU was demonstrated by the VerifyNow testing in another study of 300 patients undergoing PCI (73). In a recent prospective study of 732 patients on dual antiplatelet therapy, PR was measured before PCI using the VerifyNow P2Y₁₂ assay. Based on ROC curve analysis, an LPR cutoff of ≤ 178 PRU was associated with 30-day bleeding (area under the curve: 0.72; $p < 0.0001$) and an HPR cutoff of ≥ 239 PRU was associated with ischemic events (area under the curve: 0.68; $p < 0.0001$) (75).




Figure 1 Evidence for P2Y₁₂ Receptor Reactivity Associated With Post-PCI Ischemic and Bleeding Events

Similar to previously proposed high on-treatment platelet reactivity to ADP associated with post-PCI ischemic events, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Cutoff values for both ischemic and bleeding events based on various platelet function assays have been shown. In addition, both ischemic and bleeding events are influenced by various demographic variables. Adapted with permission from Sibbing et al. (8), Bonello et al. (9), Stone et al. (16), Alexander and Peterson (56), Gurbel et al. (59), and Campo et al. (76). ACS = acute coronary syndromes; BMI = body mass index; CABG = coronary artery bypass graft; DM = diabetes mellitus; MA = maximum amplitude; MEA = multiplate analyzer; PRI = platelet reactivity index; PRU = P2Y₁₂ reaction units; ST = stent thrombosis; TEG = thrombelastography; VASP = vasodilator stimulated phosphoprotein-phosphorylation.




Figure 2 Therapeutic Window Concept for P2Y₁₂ Receptor Reactivity

Evidence for high and low on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention (PCI) ischemic and bleeding events based on (A) VerifyNow P2Y₁₂ assay, (B) vasodilator stimulated phosphoprotein-phosphorylation assay, (C) Multiplate analyzer, and (D) thrombelastography platelet mapping assay following P2Y₁₂ receptor blocker therapy. Adapted with permission from Sibbing *et al.* (8), Bonello *et al.* (9), Gurbel *et al.* (59), and Campo *et al.* (76). AU = arbitrary aggregation units; other abbreviations as in Figure 1.

Finally, in the ADAPT-DES trial, HPR defined by >208 PRU was also inversely related to TIMI major bleeding (adjusted HR: 0.73, 95% CI: 0.61 to 0.89; $p = 0.002$) (16). This observation is consistent with the post-hoc analysis of the GRAVITAS trial, which found that the achievement of a PRU <208 was associated with significantly improved clinical outcomes (36). Thus,

evidence for a therapeutic window of optimal on-treatment PR to prevent both bleeding and ischemic events is emerging. This window would therefore inform future studies designed to optimally avoid thrombotic and bleeding events during P2Y₁₂ inhibitor therapy (8,9,16,56,59,76) (Table 3, Figs. 1 and 2).

Platelet Function Measurement During New P2Y₁₂ Inhibitor Therapy

In the platelet substudies of the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) and PLATO (Platelet Inhibition and Patient Outcomes) trials and pharmacodynamic studies of ticagrelor and prasugrel in stable CAD patients, it was observed that although the interindividual variability in response to prasugrel and ticagrelor was reduced, it was not absent (77–80). Recent studies demonstrated that HPR is not limited to clopidogrel therapy but also observed during treatment with the new and more potent P2Y₁₂ inhibitors. Moreover, the prognostic utility of PFT may also be particularly important with respect to bleeding during therapy with the new and potent P2Y₁₂ inhibitors when LPR is more frequent than during

Table 3 Platelet Reactivity Cutoff Associated With Ischemic and Bleeding Events (Therapeutic Window)

	Cutoff Associated With Ischemic Event Occurrences (References)	Cutoff Associated With Bleeding Event Occurrences (References)
VerifyNow PRU assay, PRU	>208 (16,76)	<85 (76)
Multiplate analyzer		
ADP-induced aggregation, AU	>46 (8)	<19 (8)
Thrombelastography platelet mapping assay		
ADP-induced platelet-fibrin clot strength, mm	>47 (59)	<31 (59)
VASP-PRI	≥50% (9)	<16% (9)

Abbreviations as in Table 1.

clopidogrel therapy. The cutoff values to define HPR during prasugrel and clopidogrel therapy were similar. This observation is consistent with the fact that both are thienopyridines; the mechanisms of action of their respective active metabolites are the same; they share same receptor binding site; and the active metabolites are pharmacodynamically equipotent. The similar threshold to identify at-risk patients treated with prasugrel or clopidogrel also indicates that on-treatment reactivity, rather than the drug itself, is the primary arbiter of outcome, further supporting the mechanistic principle underlying PFT-guided antiplatelet therapy.

In a recent prospective study of ST-segment elevation myocardial infarction patients undergoing PCI who were randomized to ticagrelor or prasugrel therapy, although PR did not differ between ticagrelor and prasugrel therapy, the rates of HPR (>208 PRU) measured at 2 h after dosing were 46.2% and 34.6%, respectively, and decreased significantly thereafter, not differing significantly between the 2 agents through 5 days of measurement (6). In another study, 50 patients with ST-segment elevation myocardial infarction undergoing primary PCI on bivalirudin monotherapy were randomly treated with 60-mg prasugrel or 180-mg ticagrelor loading doses. The investigators demonstrated that in only 50% of patients were both prasugrel and ticagrelor therapies effective in inhibiting PR as measured by VerifyNow assay, and at least 4 h were required to achieve an effective platelet inhibition in the majority of patients (10). These data suggest a delay in the pharmacodynamic efficacy of these drugs in selected ACS patients versus stable patients. Thus far, there are no data available on the relation between on-ticagrelor PR and bleeding/ischemic event occurrence.

Conclusions and Recommendations

HPR can be considered a risk factor for post-PCI ST and MI. The increased hazard associated with HPR has been demonstrated with various PFT. The relation between HPR and post-PCI ischemic event occurrence must be considered in the context of the overall disease risk level (i.e., ACS vs. non-ACS, diabetes vs. nondiabetes, old age, and chronic kidney disease), post-PCI time (early [e.g., before 30 days] vs. late), and ethnicity. It appears that the relation of PR to clinical outcome occurrence in the PCI setting is stronger during the initial period (up to 30 to 60 days), when intensive P2Y₁₂ inhibition may be more effective. The relationship between PR and clinical outcomes in medically-managed patients recovering from ACS may be less robust.

The large randomized trials of personalized antiplatelet therapy failed to confirm the benefit of PFT to improve outcomes in patients at low absolute overall risk, resulting in low post-discharge event rates and lack of power. These randomized studies demonstrated that event rates are low in low-risk patients undergoing PCI irrespective of PR, and that high-dose clopidogrel is not an optimal strategy

to overcome HPR and to improve clinical outcomes. Strategies employing agents that are more potent have largely remained untested in an adequate sample size of patients. The evidence from the ARCTIC and GRAVITAS trials have been used to support the hypothesis that HPR is a nonmodifiable risk factor. An alternative explanation is that the marker was not modified enough by high-dose clopidogrel or that the absolute risk of the patient population was not high enough, even though the patients had HPR.

At present, PFT is helpful in identifying high-risk patients, but its usefulness in influencing therapeutic management deserves further evaluation in large-scale trials. The overall low event rates observed in prospective trials would require enrollment of a large number of patients to definitively evaluate the utility of PFT for personalized therapy in those patient populations. Unlike the selected patients enrolled in prospective clinical studies, the risk of clinical events may be higher in routine practice, and personalized therapy may play a greater role.

An assessment of the utility of PFT in the individual patient requires the synthesis of multiple factors. The clinician should recognize the crucial role of platelet physiology in catastrophic event occurrence such as ST and should be cognizant of the guidelines. Furthermore, the clinician should be aware of the existing observational data demonstrating that HPR is a potent post-PCI risk factor while keeping in mind the results of the 2 major randomized trials, the populations studied, and the limitations of their designs. At present, it appears that PFT may be most appropriate in high-risk clopidogrel-treated patients with current or prior ACS or a history of ST. In addition, patients treated with clopidogrel who have poor left ventricular function, complex anatomy, high body mass index, and diabetes mellitus might be considered for PFT. PR should not be regarded as the sole prognostic marker for thrombotic event occurrence, but should rather be evaluated in relation to patient risk. A risk algorithm that includes PFT along with biomarker testing and clinical factors may improve risk prediction and facilitate personalization of antiplatelet therapy.


Emerging data suggest a relation of LPR to the risk of bleeding. Unselected therapy with the new P2Y₁₂ receptor blockers is associated with increased bleeding. It is also important to note that clopidogrel is pharmacodynamically effective; its use results in an adequate P2Y₁₂ receptor inhibition, according to the above-proposed definition, in about two-thirds of the patients undergoing PCI. Selectively treating these patients with generic clopidogrel rather than treating all patients with new and potent P2Y₁₂ inhibitors might provide significant cost savings. Finally, personalized antiplatelet therapy based on a concept of therapeutic window may improve the balance between better efficacy and reasonable safety. A trial to validate a therapeutic window for P2Y₁₂ inhibitors is warranted based on the information presented in this consensus document.

Reprint requests and correspondence: Dr. Paul A. Gurbel, Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 West Belvedere Avenue, Baltimore, Maryland 21215. E-mail: pgurbel@lifebridgehealth.org.

REFERENCES

- Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2011;58:e44-122.
- Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2012;60:645-81.
- Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011;32:2999-3054.
- Bonello L, Tantry US, Marcucci R, et al., for the Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol* 2010;56:919-33.
- Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation* 2003;107:2908-13.
- Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. *Circ Cardiovasc Interv* 2012;5:797-804.
- Gurbel PA, Erlinge D, Ohman EM, et al., for the TRILOGY ACS. Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS Platelet Function Substudy. *JAMA* 2012;308:1785-94.
- Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. *J Thromb Haemost* 2010;8:250-6.
- Bonello L, Mancini J, Pansieri M, et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. *J Thromb Haemost* 2012;10:1999-2005.
- Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. *J Am Coll Cardiol* 2013;61:1601-6.
- Price MJ, Berger PB, Teirstein PS, et al., for the GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 2011;305:1097-105.
- Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. *J Am Coll Cardiol* 2012;59:2159-64.
- Collet JP, Cuisset T, Rangé G, et al., for the ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. *N Engl J Med* 2012;367:2100-9.
- Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. *Circulation* 2012;125:1276-87.
- Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. *Circulation* 2012;125:1288-303.
- Stone GW, Witzenbichler B, Weisz G, et al., for the ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet* 2013;382:614-23.
- Hirsh J. Hyperactive platelets and complications of coronary artery disease. *N Engl J Med* 1987;316:1543-4.
- Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. *JAMA* 2010;303:754-62.
- Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisais DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. *Eur Heart J* 2008;29:2877-85.
- Aradi D, Komócsi A, Price MJ, et al., for the Tailored Antiplatelet Treatment Study Collaboration. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. *Int J Cardiol* 2013;167:2140-8.
- Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. *J Am Coll Cardiol* 2011;58:1945-54.
- Kirtane AJ, Parise H, Witzenbichler B, et al. Does platelet function testing add significant incremental risk stratification to unselected patients undergoing DES implantation? The ADAPT-DES study (abstr.). *J Am Coll Cardiol* 2012;59:E292.
- Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. *JAMA* 2011;306:1215-23.
- Ahn SG, Lee SH, Yoon JH, et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. *J Am Coll Cardiol Interv* 2012;5:259-67.
- Park DW, Ahn JM, Song HG, et al. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. *Am Heart J* 2013;165:34-42.
- Chirumamilla AP, Machara A, Mintz GS, et al. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. *J Am Coll Cardiol Img* 2012;5:540-9.
- Tantry US, Bliden KP, Suarez TA, Kreutz RP, Dichiaro J, Gurbel PA. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic Risk Progression (TRIP) study. *Platelets* 2010;21:360-7.
- Gori AM, Cesari F, Marcucci R, et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. *Atherosclerosis* 2009;202:255-62.
- Bernlochner I, Steinhubl S, Braun S, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. *Thromb Haemost* 2010;104:1193-200.
- Reny JL, Berdagué P, Poncet A, et al., for the ADRIE Study Group. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. *Circulation* 2012;125:3201-10.
- Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation After Deployment of Intracoronary Stent (PREDICT) score. *J Thromb Haemost* 2008;6:54-61.
- Fontana P, Berdagué P, Castelli C, et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. *J Thromb Haemost* 2010;8:2614-23.
- Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. *JAMA* 2012;307:2495-6.
- Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. *J Am Coll Cardiol* 2013;62:505-12.
- Gurbel PA, Tantry US. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. *JAMA* 2011;305:1136-7.

36. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. *Circulation* 2011;124:1132-7.
37. Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. *JAMA* 2011;306:2221-8.
38. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. *J Am Coll Cardiol* 2008;51:1404-11.
39. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. *Am J Cardiol* 2009;103:5-10.
40. Campo G, Fileti L, de Cesare N, et al., on behalf of the 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel) trial substudy. *J Am Coll Cardiol* 2010;56:1447-55.
41. Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. *J Am Coll Cardiol Interv* 2008;1:649-53.
42. Siller-Matula JM, Francesconi M, Dechant C, et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. *Int J Cardiol* 2013;167:2018-23.
43. Hazarbasanov D, Velchev V, Finkov B, et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. *J Thromb Thrombolysis* 2012;34:85-90.
44. Bhatt DL. Prasugrel in clinical practice. *N Engl J Med* 2009;361:940-2.
45. Tantry US, Gurbel PA. Assessment of oral antithrombotic therapy by platelet function testing. *Nat Rev Cardiol* 2011;8:572-9.
46. Geisler T, Zürn C, Simonenko R, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. *Eur Heart J* 2010;31:59-66.
47. Chhatrwalla AK, Amin AP, Kennedy KF, et al., for the National Cardiovascular Data Registry. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. *JAMA* 2013;309:1022-9.
48. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011;123:2736-47.
49. Ndrepepa G, Berger PB, Mehilil J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. *J Am Coll Cardiol* 2008;51:690-7.
50. Berger PB, Bhatt DL, Fuster V, et al., for the CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Circulation* 2010;121:2575-83.
51. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. *J Am Coll Cardiol* 2009;53:2019-27.
52. Roy P, Bonello L, Torguson R, et al. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. *Am J Cardiol* 2008;102:1614-7.
53. Thygesen K, Alpert JS, White HD, for the Joint ESC/ACC/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Eur Heart J* 2007;28:2525-38.
54. Cutlip DE, Windecker S, Mehran R, et al., for the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 2007;115:2344-51.
55. Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. *Thromb Haemost* 2013;109:817-24.
56. Alexander KP, Peterson ED. Minimizing the risks of anticoagulants and platelet inhibitors. *Circulation* 2010;121:1960-70.
57. Quinlan DJ, Eikelboom JW, Goodman SG, et al. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. *Eur Heart J* 2011;32:2256-65.
58. Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? *EuroIntervention* 2009;5:325-9.
59. Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. *Am Heart J* 2010;160:346-54.
60. Mokhtar OA, Lemesle G, Armero S, et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. *Thromb Res* 2010;126:e147-9.
61. Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). *Am J Cardiol* 2011;107:995-1000.
62. Tsukahara K, Kimura K, Morita S, et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. *Circ J* 2010;74:679-85.
63. Parodi G, Bellandi B, Venditti F, et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. *Am J Cardiol* 2012;109:214-8.
64. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. *J Am Coll Cardiol* 2012;60:193-9.
65. Alexopoulos D, Xanthopoulou I, Siapika A, et al. Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients. *Int J Cardiol* 2013;168:629-30.
66. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 2004;128:425-31.
67. Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) study. *Circ Cardiovasc Interv* 2012;5:261-9.
68. Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. *J Am Coll Cardiol* 2010;56:1994-2002.
69. Ranucci M, Baryshnikova E, Soro G, et al. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. *Ann Thorac Surg* 2011;91:123-9.
70. Ferraris VA, Saha SP, Oestreich JH, et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. *Ann Thorac Surg* 2012;94:1761-81.
71. Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. *Am J Cardiol* 2006;98:681-4.
72. Price MJ, Teirstein PS. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. *Am J Cardiol* 2008;102:790-5.
73. Price MJ, Walder JS, Baker BA, et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease. *J Am Coll Cardiol* 2012;59:2338-43.
74. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol* 2007;50:1822-34.

75. Mangiacapra F, Patti G, Barbato E, et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. *J Am Coll Cardiol Intv* 2012;5:281–9.
 76. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. *J Am Coll Cardiol* 2011;57:2474–83.
 77. Michelson AD, Frelinger AL 3rd, Braunwald E, et al., for the TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. *Eur Heart J* 2009;30:1753–63.
 78. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet Inhibition and Patient Outcomes) PLATELET substudy. *J Am Coll Cardiol* 2010;56:1456–62.
 79. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y₁₂ receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. *Eur Heart J* 2008;29:21–30.
 80. Gurbel PA, Bliden KP, Butler KD, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. *Circulation* 2009;120:2577–85.
-
- Key Words:** adenosine diphosphate ■ bleeding ■ consensus ■ ischemia ■ platelet reactivity.
-
-  **APPENDIX**
-
- For supplemental information regarding guidelines, please see the online version of this article.**